Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr.

J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.

PMID:
31682550
2.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

PMID:
30557521
3.

Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.

Joe AK, Schnoll-Sussman F, Bresalier RS, Abrams JA, Hibshoosh H, Cheung K, Friedman RA, Yang CS, Milne GL, Liu DD, Lee JJ, Abdul K, Bigg M, Foreman J, Su T, Wang X, Ahmed A, Neugut AI, Akpa E, Lippman SM, Perloff M, Brown PH, Lightdale CJ.

Cancer Prev Res (Phila). 2015 Dec;8(12):1131-7. doi: 10.1158/1940-6207.CAPR-14-0274-T. Epub 2015 Oct 15.

4.

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.

Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SP, Grippo JF.

Pharmacol Res Perspect. 2015 Mar;3(2):e00113. doi: 10.1002/prp2.113.

5.

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.

Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF.

J Clin Pharmacol. 2014 Apr;54(4):368-74. doi: 10.1002/jcph.255. Epub 2014 Jan 22.

PMID:
24374975
6.

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.

Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A.

Cancer Chemother Pharmacol. 2014 Jan;73(1):103-11. doi: 10.1007/s00280-013-2324-5. Epub 2013 Nov 1.

PMID:
24178368
7.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.

J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.

PMID:
23569304
8.

Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK.

Oncologist. 2013;18(3):314-22. doi: 10.1634/theoncologist.2012-0333. Epub 2013 Mar 1.

9.

Somatic evolution of head and neck cancer - biological robustness and latent vulnerability.

Masuda M, Toh S, Wakasaki T, Suzui M, Joe AK.

Mol Oncol. 2013 Feb;7(1):14-28. doi: 10.1016/j.molonc.2012.10.009. Epub 2012 Nov 2. Review.

10.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A.

N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.

11.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

12.

A case of laryngeal carcinoma in a young adult with dyskeratosis congenita.

Komune N, Hara T, Tamae A, Izu K, Tokura Y, Joe AK, Masuda M.

Int J Clin Oncol. 2010 Aug;15(4):428-32. doi: 10.1007/s10147-010-0053-x. Epub 2010 Mar 4.

PMID:
20198396
13.

Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers?

Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, Weinstein IB.

Curr Cancer Drug Targets. 2010 Feb;10(1):117-26. Review.

PMID:
20088788
14.

Fear and loathing in the Caribbean: three studies of fear and cancer screening in Brooklyn's immigrant Caribbean subpopulations.

Consedine NS, Adjei BA, Horton D, Joe AK, Borrell LN, Ramirez PM, Ungar T, McKiernan JM, Jacobson JS, Magai C, Neugut AI.

Infect Agent Cancer. 2009 Feb 10;4 Suppl 1:S14. doi: 10.1186/1750-9378-4-S1-S14. No abstract available.

15.

p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047.

Adachi S, Natsume H, Yamauchi J, Matsushima-Nishiwaki R, Joe AK, Moriwaki H, Kozawa O.

Cancer Lett. 2009 May 8;277(1):108-13. doi: 10.1016/j.canlet.2008.11.034. Epub 2009 Jan 12.

PMID:
19138820
16.

Inhibition of BCL2 expression and activity increases H460 sensitivity to the growth inhibitory effects of polyphenon E.

Borgovan T, Bellistri JP, Slack KN, Kopelovich L, Desai M, Joe AK.

J Exp Ther Oncol. 2009;8(2):129-44.

17.

(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells.

Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H, Maxfield FR, Weinstein IB.

Carcinogenesis. 2008 Oct;29(10):1986-93. doi: 10.1093/carcin/bgn128. Epub 2008 Jun 26.

18.

Comparing genetic ancestry and self-described race in african americans born in the United States and in Africa.

Yaeger R, Avila-Bront A, Abdul K, Nolan PC, Grann VR, Birchette MG, Choudhry S, Burchard EG, Beckman KB, Gorroochurn P, Ziv E, Consedine NS, Joe AK.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1329-38. doi: 10.1158/1055-9965.EPI-07-2505.

19.

Prevention of bone loss after withdrawal of tamoxifen.

Cohen A, Fleischer JB, Johnson MK, Brown IN, Joe AK, Hershman DL, McMahon DJ, Silverberg SJ.

Endocr Pract. 2008 Mar;14(2):162-7.

20.

17HSD 2 may be higher in African-American breast cancer and is associated with estrogen receptor-negative tumors.

Yaeger R, Nolan PC, Su T, Avila-Bront A, Wang X, Cheung YK, Liu H, Rangarajan VS, Hibshoosh H, Powell CA, Joe AK.

Cancer Genomics Proteomics. 2007 Sep-Oct;4(5):341-8.

21.

A case of primary Hodgkin's lymphoma of the parotid gland.

Masuda M, Segawa Y, Joe AK, Hirakawa N, Komune S.

Auris Nasus Larynx. 2008 Sep;35(3):440-2. Epub 2007 Nov 5.

PMID:
17983719
22.

Fear, knowledge, and efficacy beliefs differentially predict the frequency of digital rectal examination versus prostate specific antigen screening in ethnically diverse samples of older men.

Consedine NS, Horton D, Ungar T, Joe AK, Ramirez P, Borrell L.

Am J Mens Health. 2007 Mar;1(1):29-43. doi: 10.1177/1557988306293495.

PMID:
19482781
23.

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Weinstein IB, Joe AK.

Nat Clin Pract Oncol. 2006 Aug;3(8):448-57. Review.

PMID:
16894390
24.

Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.

Lim JT, Joe AK, Suzui M, Shimizu M, Masuda M, Weinstein IB.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3478-84.

25.

EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.

Shimizu M, Deguchi A, Joe AK, Mckoy JF, Moriwaki H, Weinstein IB.

J Exp Ther Oncol. 2005;5(1):69-78.

PMID:
16416603
26.

African-American/White differences in breast carcinoma.

Joe AK, Hibshoosh H.

Cancer. 2005 Aug 1;104(3):661-2; author reply 662-3. No abstract available.

27.

Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer.

Joe AK, Memeo L, Mckoy J, Mansukhani M, Liu H, Avila-Bront A, Romero J, Li H, Troxel A, Hibshoosh H.

Anticancer Res. 2005 Jan-Feb;25(1A):273-81.

28.

Supplementing previously treated anestrous dairy cows with progesterone does not increase first-service conception rate.

Hanlon DW, Davidson PJ, Hittmann AR, Joe AK.

Theriogenology. 2005 Jan 1;63(1):239-45.

PMID:
15589287
29.

Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.

Joe AK, Liu H, Xiao D, Soh JW, Pinto JT, Beer DG, Piazza GA, Thompson WJ, Weinstein IB.

J Exp Ther Oncol. 2003 Mar-Apr;3(2):83-94.

30.

Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network Symposium.

Antman K, Abraido-Lanza AF, Blum D, Brownfield E, Cicatelli B, Debor MD, Emmons K, Fitzgibbon M, Gapstur SM, Gradishar W, Hiatt RA, Hubbell FA, Joe AK, Klassen AC, Lee NC, Linden HM, McMullin J, Mishra SI, Neuhaus C, Olopade FI, Walas K.

Breast Cancer Res Treat. 2002 Oct;75(3):269-80.

PMID:
12353816
31.

Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines.

Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB.

Clin Cancer Res. 2002 Mar;8(3):893-903.

32.

Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer.

Joe AK, Arber N, Bose S, Heitjan D, Zhang Y, Weinstein IB, Hibshoosh H.

Anticancer Res. 2001 Sep-Oct;21(5):3535-9.

PMID:
11848520
33.

Complementary and alternative medicine: the role of the cancer center.

Antman K, Benson MC, Chabot J, Cobrinik D, Grann VR, Jacobson JS, Joe AK, Katz AE, Kelly K, Neugut AI, Russo D, Tiersten A, Weinstein IB.

J Clin Oncol. 2001 Sep 15;19(18 Suppl):55S-60S. No abstract available.

PMID:
11560974
34.

The transmembrane domains of Sindbis virus envelope glycoproteins induce cell death.

Joe AK, Foo HH, Kleeman L, Levine B.

J Virol. 1998 May;72(5):3935-43.

35.

Dominant inhibitory Ras delays Sindbis virus-induced apoptosis in neuronal cells.

Joe AK, Ferrari G, Jiang HH, Liang XH, Levine B.

J Virol. 1996 Nov;70(11):7744-51.

Supplemental Content

Support Center